Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double‐blind, placebo‐controlled trial of the angiotensin‐converting enzyme inhibitor quinapril

Gliddon, A.; J Doré, Caroline; M. Black, C.; McHugh, NJ; Moots, RJ; P. Denton, Christopher; L. Herrick, Ariane; Barnes, Theresa; Camilleri, Jean-Pierre; Chakravarty, Kuntal; Emery, Paul; Griffiths, Bridget; Hopkinson, Neil; Hickling, P; Lanyon, Peter; Laversuch, Catherine; Lawson, Tom; K Mallya, R; K Nisar, Muhammad; Rhys-Dillon, Ceril; Sheeran, Tom; J. Maddison, Peter

doi:10.1002/art.22965

Public

Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double‐blind, placebo‐controlled trial of the angiotensin‐converting enzyme inhibitor quinapril

Published in Arthritis & Rheumatism • Oct 29, 2007

Authors:

A. Gliddon

Caroline J Doré

C. M. Black

Abstract

OBJECTIVE: To evaluate the efficacy and tolerability of prolonged administration of quinapril, a long-acting angiotensin-converting enzyme inhibitor, in the management of the peripheral vascular manifestations of limited cutaneous systemic sclerosis (lcSSc) and in the prevention of the progression o...

Subject

Quinapril

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!